CeriBell, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
CeriBell, Inc. (Nasdaq: CBLL), a medical technology company focused on neurological conditions, has successfully closed its upsized initial public offering (IPO). The company sold 12,196,969 shares of common stock at $17.00 per share, including 1,590,909 additional shares from the full exercise of the underwriters' option. The IPO raised approximately $207.3 million in gross proceeds before deducting underwriting discounts, commissions, and other expenses.
CeriBell's common stock began trading on the Nasdaq Global Select Market on October 11, 2024, under the ticker symbol CBLL. BofA Securities and J.P. Morgan served as joint book-running managers and representatives of the underwriters, with William Blair, TD Cowen, and Canaccord Genuity acting as co-managers for the offering.
CeriBell, Inc. (Nasdaq: CBLL), un'azienda di tecnologia medica focalizzata sulle condizioni neurologiche, ha concluso con successo la sua offerta pubblica iniziale (IPO) ampliata. L'azienda ha venduto 12.196.969 azioni di capitale comune a 17,00 dollari per azione, comprese 1.590.909 azioni aggiuntive derivanti dall'esercizio completo dell'opzione degli underwriter. L'IPO ha raccolto circa 207,3 milioni di dollari in proventi lordi prima della deduzione degli sconti di sottoscrizione, delle commissioni e di altre spese.
Le azioni comuni di CeriBell hanno iniziato a essere scambiate sul Nasdaq Global Select Market l'11 ottobre 2024, con il simbolo ticker CBLL. BofA Securities e J.P. Morgan hanno operato come gestori congiunti dell'offerta e rappresentanti degli underwriter, mentre William Blair, TD Cowen e Canaccord Genuity hanno agito come co-gestori dell'offerta.
CeriBell, Inc. (Nasdaq: CBLL), una empresa de tecnología médica enfocada en condiciones neurológicas, ha cerrado con éxito su oferta pública inicial (IPO) ampliada. La empresa vendió 12.196.969 acciones de capital común a 17,00 dólares por acción, incluyendo 1.590.909 acciones adicionales por el ejercicio completo de la opción de los suscriptores. La IPO recaudó aproximadamente 207,3 millones de dólares en ingresos brutos antes de deducir descuentos por suscripción, comisiones y otros gastos.
Las acciones comunes de CeriBell comenzaron a cotizar en el Nasdaq Global Select Market el 11 de octubre de 2024, bajo el símbolo ticker CBLL. BofA Securities y J.P. Morgan actuaron como gerentes conjuntos de la oferta y representantes de los suscriptores, mientras que William Blair, TD Cowen y Canaccord Genuity actuaron como co-gerentes de la oferta.
CeriBell, Inc. (Nasdaq: CBLL)는 신경학적 질환에 중점을 둔 의료 기술 회사로, 성공적으로 증권 공개를 확대하였습니다. 이 회사는 12,196,969주의 보통주를 주당 17.00달러에 판매하였으며, 이에는 인수자 옵션의 전량 행사로 인한 추가 1,590,909주가 포함됩니다. 이번 IPO에서 약 2억 730만 달러의 총 수익이 발생하였으며, 이는 인수 수수료, 커미션 및 기타 비용을 공제하기 전의 금액입니다.
CeriBell의 보통주는 2024년 10월 11일부터 Nasdaq Global Select Market에서 CBLL이라는 티커 기호로 거래되기 시작하였습니다. BofA Securities와 J.P. Morgan이 공동 북런닝 매니저 및 인수인의 대표로 활동하였으며, William Blair, TD Cowen, Canaccord Genuity가 이번 공모의 공동 관리자로 활동하였습니다.
CeriBell, Inc. (Nasdaq: CBLL), une entreprise de technologie médicale axée sur les affections neurologiques, a réussi à clôturer son introduction en bourse (IPO) augmentée. L'entreprise a vendu 12.196.969 actions ordinaires au prix de 17,00 dollars par action, y compris 1.590.909 actions supplémentaires en raison de l'exercice intégral de l'option des souscripteurs. L'IPO a permis de lever environ 207,3 millions de dollars de produits bruts avant déduction des remises sur souscription, des commissions et d'autres frais.
Les actions ordinaires de CeriBell ont commencé à être négociées sur le Nasdaq Global Select Market le 11 octobre 2024, sous le symbole boursier CBLL. BofA Securities et J.P. Morgan ont été les co-managers de livre et les représentants des souscripteurs, tandis que William Blair, TD Cowen et Canaccord Genuity ont agi en tant que co-managers de l'émission.
CeriBell, Inc. (Nasdaq: CBLL), ein Medizintechnologieunternehmen mit Fokus auf neurologische Erkrankungen, hat erfolgreich seine erweiterte Börseneinführung (IPO) abgeschlossen. Das Unternehmen hat 12.196.969 Aktien des Stammkapitals zu einem Preis von 17,00 Dollar pro Aktie verkauft, einschließlich 1.590.909 zusätzliche Aktien durch die vollständige Ausübung der Option der Underwriter. Die IPO brachte etwa 207,3 Millionen Dollar an Bruttoerlösen ein, bevor Unterzeichnungssachgebühren, Provisionen und andere Kosten abgezogen wurden.
Die Stammaktien von CeriBell begannen am 11. Oktober 2024 im Nasdaq Global Select Market unter dem Tickersymbol CBLL zu handeln. BofA Securities und J.P. Morgan fungierten als Joint-Bookrunner und Vertreter der Underwriter, während William Blair, TD Cowen und Canaccord Genuity als Co-Manager der Emission tätig waren.
- Successful closing of upsized IPO, raising approximately $207.3 million in gross proceeds
- Full exercise of underwriters' option to purchase additional shares, indicating strong demand
- Listing on the Nasdaq Global Select Market, potentially increasing visibility and liquidity
- Potential dilution of existing shareholders due to the issuance of new shares
Insights
CeriBell's successful IPO and full exercise of the underwriters' option demonstrate strong investor confidence in the company's potential. The
The upsized offering of 12,196,969 shares at
The involvement of major underwriters like BofA Securities and J.P. Morgan adds credibility to the offering. For investors, this IPO represents an opportunity to participate in the growing medical technology sector, specifically in neurology. However, as with any newly public company, investors should be aware of potential volatility and the need for CeriBell to execute on its growth strategy to justify its valuation.
CeriBell's focus on transforming diagnosis and management of serious neurological conditions positions it at the forefront of a critical medical need. The substantial capital raised through this IPO will likely accelerate research and development efforts, potentially leading to innovative solutions in neurology.
The company's commercial-stage status suggests it has already developed marketable products, which reduces some investment risk compared to pre-revenue biotech firms. However, the medical technology sector is highly competitive and regulated, requiring continuous innovation and regulatory compliance.
Investors should monitor CeriBell's progress in expanding its product portfolio, securing regulatory approvals and gaining market share. The company's ability to improve patient outcomes and reduce healthcare costs will be important for long-term success. This IPO could catalyze advancements in neurological care, potentially benefiting both patients and shareholders if CeriBell can successfully execute its strategy.
BofA Securities and J.P. Morgan acted as joint book-running managers and as representatives of the underwriters for the offering. William Blair, TD Cowen and Canaccord Genuity acted as co-managers for the offering.
A registration statement relating to the shares sold in this offering was filed with the Securities and Exchange Commission and became effective on October 10, 2024. The offering was made only by means of a prospectus, copies of which may be obtained from BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street,
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Ceribell
Ceribell is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Ceribell System is an AI-powered, rapidly deployable point-of-care electroencephalography ("EEG") platform designed to address the unmet needs of patients in the acute care setting. The company is headquartered in
INVESTOR CONTACT
Brian Johnston or Laine Morgan
Gilmartin Group, LLC
investors@ceribell.com
MEDIA CONTACT
Corrie Rose
Press@ceribell.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ceribell-inc-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-302277031.html
SOURCE Ceribell, Inc.
FAQ
How many shares did CeriBell (CBLL) sell in its IPO?
What was the price per share for CeriBell's (CBLL) IPO?
How much did CeriBell (CBLL) raise in its IPO?
When did CeriBell (CBLL) begin trading on the Nasdaq?
Who were the underwriters for CeriBell's (CBLL) IPO?
